Experiencia de uso de partículas DC Bead ® cargadas con doxorrubicina en quimioembolización hepática

Muros-Ortega, M; Díaz-Carrasco, M. S; Vila-Clérigues, N; Mendoza-Otero, F; Rubia, A. de la; Capel Alemán, A.
Farm. hosp ; 35(4): 172-179, jul.-ago. 2011. tab
Artículo en Español | IBECS (España) | ID: ibc-107328

Documentos relacionados

  1. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis.
  2. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
  3. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
  4. [Microsphere TACE with Arterial Infusion of Bevacizumab for Portal Vein Tumor Thrombus by Hepatocellular Carcinoma].
  5. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.
  6. Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization.
  7. Polyethylene Glycol Drug-Eluting Embolic Microspheres Loaded with Doxorubicin for the Treatment of Hepatocellular Carcinoma: Feasibility, Safety, and Pharmacokinetic Study.
  8. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy.
  9. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.
  10. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.